Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ. Cocquyt V, et al. Among authors: gertz bj. Eur J Cancer. 2001 May;37(7):835-42. doi: 10.1016/s0959-8049(00)00416-0. Eur J Cancer. 2001. PMID: 11313170 Clinical Trial.
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ. Van Belle S, et al. Among authors: gertz bj. Cancer. 2002 Jun 1;94(11):3032-41. doi: 10.1002/cncr.10516. Cancer. 2002. PMID: 12115394 Free article. Clinical Trial.
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ. Campos D, et al. Among authors: gertz bj. J Clin Oncol. 2001 Mar 15;19(6):1759-67. doi: 10.1200/JCO.2001.19.6.1759. J Clin Oncol. 2001. PMID: 11251007 Clinical Trial.
Pharmacokinetics of intravenous alendronate.
Cocquyt V, Kline WF, Gertz BJ, Van Belle SJ, Holland SD, DeSmet M, Quan H, Vyas KP, Zhang KE, De Grève J, Porras AG. Cocquyt V, et al. Among authors: gertz bj. J Clin Pharmacol. 1999 Apr;39(4):385-93. doi: 10.1177/00912709922007958. J Clin Pharmacol. 1999. PMID: 10197297 Clinical Trial.
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ. Schwartz JI, et al. Among authors: gertz bj. Clin Pharmacol Ther. 2000 Dec;68(6):626-36. doi: 10.1067/mcp.2000.112244. Clin Pharmacol Ther. 2000. PMID: 11180023 Clinical Trial.
94 results